[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100530171":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":44,"responsibleParty":60,"collaborators":62,"id":70,"slug":26,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":26,"eligibilityCriteria":74,"healthyVolunteers":71,"sex":75,"minAge":76,"maxAge":26,"enrollmentInfo":77,"targetDuration":26,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":88,"overallStatus":47,"whyStopped":26,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Universidade Federal Fluminense","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Nattokinase group","EXPERIMENTAL","Participants will receive 1 capsule per day, providing the active nattokinase daily, at a dosage of 100mg, standardized at 2,000 Fibrinolytic Units.",[13],"Dietary Supplement: Nattokinase",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo Group","PLACEBO_COMPARATOR","The placebo group will receive the same amount of 100mg placebo, at the same time, containing corn starch.",[19],"Dietary Supplement: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DIETARY_SUPPLEMENT","Nattokinase","Participants will receive 1 capsule per day, providing the active nattokinase daily, at a dosage of 100mg, standardized at 2,000 Fibrinolytic Units for 2 months",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","The placebo group will receive 1 capsule per day with 100mg containing corn starch for 2 months.",[15],[32],{"name":33,"affiliation":5,"role":34},"Ludmila Cardozo, PhD","PRINCIPAL_INVESTIGATOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Denise Mafra, PhD","CONTACT","+5521985683003","dmafra30@gmail.com",{"name":33,"role":38,"phone":42,"phoneExt":26,"email":43},"+5521987333185","ludmila.cardozo@gmail.com",[45],{"facility":46,"status":47,"city":48,"state":48,"zip":49,"country":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Denise Mafra","RECRUITING","Rio de Janeiro","22260050","Brazil",{"type":52,"coordinates":53},"Point",[54,55],-43.18223,-22.90642,{"lat":55,"lon":54},[58],{"name":59,"role":38,"phone":26,"phoneExt":26,"email":26},"Ludmila cardozo, phd",{"type":61,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[63,66,68],{"name":64,"class":65},"Conselho Nacional de Desenvolvimento Científico e Tecnológico","OTHER_GOV",{"name":67,"class":65},"Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.",{"name":69,"class":65},"Rio de Janeiro State Research Supporting Foundation (FAPERJ)","100530171",false,"NCT06183307","Effects of Nattokinase on Inflammation and Cardiovascular Risk Markers in Patients With Dyslipidemia","Inclusion Criteria:\n\n* Both sexes;\n* Over 18 years of age;\n* Isolated increase in LDL-c (LDL-c ≥ 160 mg\u002FdL);\n* Isolated increase in triglycerides (TG ≥ 150 mg\u002FdL or ≥ 175 mg\u002FdL, without fasting);\n* increased LDL-c (LDL-c ≥ 160 mg\u002FdL)\n* TG (TG ≥ 150 mg\u002FdL or ≥ 175 mg\u002FdL, without fasting);\n* Reduction in HDL-c (men \\\u003C 40 mg\u002FdL and women \\\u003C 50 mg\u002FdL) alone or in association with an increase in LDL-c or TG. If TG ≥ 400 mg\u002FdL.\n* Individuals who are already using lipid-lowering therapy (statins or non-statins) will also be included.\n\nExclusion Criteria:\n\n* Participants with autoimmune and infectious diseases, diabetes, cancer and AIDS;\n* Pregnant women;\n* Participants using catabolic drugs or antibiotics\n* Participants on anticoagulant medication\n* Participants using antioxidant vitamin supplements, prebiotic, probiotic or synbiotic and who are allergic to corn or soy starch.","ALL","18 Years",{"count":78,"type":79},48,"ESTIMATED","INTERVENTIONAL",[82],"NA","The study aims to evaluate the effect of the nattokinase enzyme on inflammation and markers of cardiovascular risk in participants with dyslipidemia. A longitudinal double-blind randomized clinical trial will be carried out, involving hypertensive participants with dyslipidemia for two months.",[85,86,87],"Cardiovascular Diseases","Dyslipidemias","Inflammation",[89,85,87,90],"nattokinase","fibrinogen","2026-05-12",{"date":93,"type":94},"2026-05-14","ACTUAL",{"date":96,"type":94},"2024-08-03",{"date":98,"type":79},"2026-12-20",{"name":5,"class":6},1]